Analysts think KZIA stock price could increase by 452%
Aug 02, 2024, 6:25 AM
19.50%
What does KZIA do
Kazia Therapeutics Ltd, based in Sydney, Australia, specializes in oncology drug development with key projects including Paxalisib for brain cancer and EVT801 targeting VEGFR3 in various cancers. The company focuses on pharmaceutical research and development, addressing critical pathways in cancer cell growth and metastasis.
3 analysts think KZIA stock price will increase by 452.21%. The current median analyst target is $1.95 compared to a current stock price of $0.35. The lowest analysts target is $1.93 and the highest analyst target is $2.01.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.